Ventus Therapeutics logo

Ventus Therapeutics Funding & Investors

Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.

ventustx.com

Total Amount Raised: $370,150,016

Ventus Therapeutics Funding Rounds

  • Grant

    $150,000

    Grant Investors

    Michael J Fox Foundation
  • Corporate Round

    $70,000,000

    Corporate Round Investors

    Novo Nordisk
  • Series C

    $140,000,000

    Series C Investors

    Ra Capital Management
    SoftBank Vision Fund
    Alexandria Venture Investments
    Qatar Investment Authority
    GV
    Biotechnology Value Fund
    Casdin Capital
    Fonds de solidarité FTQ
    Cormorant Asset Management
    Versant Ventures
    Andreessen Horowitz
  • Series B

    $100,000,000

    Series B Investors

    Ra Capital Management
    Alexandria Venture Investments
    GV
    Biotechnology Value Fund
    Casdin Capital
    Versant Ventures
    Fonds de solidarité FTQ
    Cormorant Asset Management
  • Series A

    $60,000,000

    Series A Investors

    Versant Ventures
    GV
Funding info provided by Diffbot.